US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Defiance Daily Target 2X Long NVO ETF

14.88

+0.05000.34%

Volume:220.88K

Turnover:3.29M

Market Cap:38.51M

PE:- -

High:15.17

Open:15.07

Low:14.73

Close:14.83

52wk High:36.00

52wk Low:9.23

Shares:2.59M

Float Shares:2.59M

Volume Ratio:0.66

T/O Rate:8.53%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Novo Nordisk’s AMAZE 9 Oral Obesity Trial: A New Pill in the Weight-Loss Race

Novo Nordisk A/S Series B Stock Falls Monday, Underperforms Market

Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme

Lexicon Pharma Earns $10 Million Milestone Payment from Novo Nordisk

Lexicon earns third $10M milestone payment from Novo Nordisk for LX9851

Hong Kong Memory Chip Stocks Plunge as Samsung Drops Nearly 8%, Leveraged Product Sinks 16%

South Korea Sees Surge in Seized Illegal Weight-Loss Drugs, Tripling Last Year's Total in Just Six Months

Novo Nordisk A/S Series B Stock Rises Friday, Outperforms Market

Novonesis Expects Results from Weight-Loss Drug Supplement Study in 2027

Moderately bullish activity in Novo Nordisk with shares up 1.32%

Novo Nordisk Adds a New Early-Stage Obesity Drug to Its Pipeline

Novo Nordisk A/S Series B Stock Rises Wednesday, Outperforms Market

These ‘Innovative’ ETFs Have Been Disastrous for Investors

Why 2026 is Biotech's Comeback Year

Novo Nordisk testing lower doses of oral Wegovy, Reuters reports

Novo Nordisk Starts Testing Lower-Doses of Its Wegovy Weight-Loss Pills

Novo Nordisk Launches Dosage Study for Oral Semaglutide

MT Newswires Live

Pharmaceutical Giants Race to Develop Obesity Drugs Without Severe Side Effects

Novo Nordisk Tests Semaglutide’s Alzheimer’s Potential: What Investors Should Watch

BMO Capital Remains a Hold on Novo Nordisk (NVO)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/NVOX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVOX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","market":"US","secType":"STK","nameCN":"Defiance Daily Target 2X Long NVO ETF","latestPrice":14.88,"timestamp":1787596490930,"preClose":14.83,"halted":0,"volume":220876,"delay":0,"changeRate":0.0033715441672286387,"floatShares":2588101,"shares":2588101,"eps":0,"marketStatus":"Trading","change":0.05,"latestTime":"08-24 14:35:53 EDT","open":15.07,"high":15.17,"low":14.725,"amount":3286630.2416040003,"amplitude":0.030007,"askPrice":14.86,"askSize":150,"bidPrice":14.85,"bidSize":50,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":14.83,"sharesOutstanding":4098101,"nav":14.48,"aum":37475702.48,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":15.12,"preClose":14.83,"latestTime":"09:26 EDT","volume":2020,"amount":30494.513880000002,"timestamp":1787577963186,"change":0.29,"changeRate":0.019555,"amplitude":0.019299},"postHourTrading":{"tag":"盘后","latestPrice":14.83,"preClose":14.83,"latestTime":"19:55 EDT","volume":568,"amount":8425.3584,"timestamp":1787356551278,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.65735,"impliedVol":0.5845,"impliedVolPercentile":0.028},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","floatShares":2588101,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.65735,"shares":2588101,"dividePrice":0,"high":15.17,"amplitude":0.030007,"preClose":14.83,"low":14.725,"week52Low":9.23,"pbRate":"--","week52High":36,"institutionHeld":0,"latestPrice":14.88,"committee":-0.5,"eps":0,"divideRate":0,"volume":220876,"delay":0,"ttmEps":0,"open":15.07,"prevYearClose":21.89,"prevWeekClose":14.83,"prevMonthClose":15.035,"prevQuarterClose":16.05,"fiveDayClose":13.72,"twentyDayClose":16.94,"sixtyDayClose":14.89},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVOX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-12-09","symbol":"NVOX","defaultRemindTime":1765290600000,"type":"split","dateTimestamp":1765256400000,"forFactor":8,"toFactor":1,"ratio":8}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVOX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVOX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVOX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662270747","title":"Novo Nordisk’s AMAZE 9 Oral Obesity Trial: A New Pill in the Weight-Loss Race","url":"https://stock-news.laohu8.com/highlight/detail?id=2662270747","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662270747?lang=en_us&edition=fundamental","pubTime":"2026-08-25 00:31","pubTimestamp":1787589070,"startTime":"0","endTime":"0","summary":"Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk A/S (NVO) has launched AMAZE 9, a Phase 3 obesity study title...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisks-amaze-9-oral-obesity-trial-a-new-pill-in-the-weight-loss-race?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisks-amaze-9-oral-obesity-trial-a-new-pill-in-the-weight-loss-race?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVO","LU1093756168.USD","BK4007","LU0154236417.USD","LU1093756325.SGD","BK4588","THNR","IE00BZ1G4Q59.USD","BK4585","NVOC","OZEM","NVOH","IE00BKVL7J92.USD","BK4532","BK4599","PPH","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662270631","title":"Novo Nordisk A/S Series B Stock Falls Monday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2662270631","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662270631?lang=en_us&edition=fundamental","pubTime":"2026-08-25 00:02","pubTimestamp":1787587320,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novo Nordisk A/S Series B dropped 0.5% to DKK299.25 Monday on what proved to be an overall unfavorable trading session for the stock market, with the OMX Nordic 40 Index falling 0.3% to 2,710.02.The company closed DKK110.70 below its 52-week high of DKK409.95, which the company reached on January 23, 2026.Trading volume was 3,241,705, compared to the 50-day average trading volume of 4,317,428.Data source: Dow Jones Market Data, FactSet","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOC","NVOH","BK4599","PPH","BK4532","BK4588","BK4007","THNR","LU0154236417.USD","BK4585","NVO","NVOX","IE00BKVL7J92.USD","OZEM","LU1093756168.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661727717","title":"Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme","url":"https://stock-news.laohu8.com/highlight/detail?id=2661727717","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661727717?lang=en_us&edition=fundamental","pubTime":"2026-08-24 23:18","pubTimestamp":1787584692,"startTime":"0","endTime":"0","summary":"Novo Nordisk ( ($NVO) ) has issued an announcement. On 6 May 2026, Novo Nordisk launched a share repurchase programme under EU Safe Harbour rules a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-details-progress-in-dkk-15-billion-share-buyback-programme-4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-details-progress-in-dkk-15-billion-share-buyback-programme-4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IE00BZ1G4Q59.USD","BK4532","LU1093756168.USD","NVOX","LU1093756325.SGD","IE00BKVL7J92.USD","BK4599","PPH","BK4588","NVOC","LU0154236417.USD","THNR","OZEM","NVO","BK4007","NVOH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661271595","title":"Lexicon Pharma Earns $10 Million Milestone Payment from Novo Nordisk","url":"https://stock-news.laohu8.com/highlight/detail?id=2661271595","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661271595?lang=en_us&edition=fundamental","pubTime":"2026-08-24 21:12","pubTimestamp":1787577120,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals has earned a third $10 million milestone payment from Novo Nordisk for hitting a key milestone in the clinical development program for its obesity drug.The biopharmaceutical company on Monday said that it has achieved a patient dosing milestone in the continuing phase 1 program for LX9851, a treatment being developed for obesity and associated metabolic disorders.Lexicon and Novo Nordisk signed an exclusive worldwide license agreement for LX9851 last year, under which Novo Nordisk is able to develop, manufacture and commercialize the drug for all indications.So far, Lexicon has earned $75 million of the $1 billion in potential upfront, development, regulatory and commercial milestone payments available under its Novo Nordisk collaboration. Lexicon is also entitled to receive tiered royalties on future LX9851 sales.The development program for LX9851 was kicked off by Novo Nordisk in March to investigate the safety, tolerability, pharmacokinetics and pharmacodynam","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BKVL7J92.USD","BK4585","BK4532","NVOC","BK4007","LU0154236417.USD","OZEM","NVOX","LU1093756325.SGD","IE00BZ1G4Q59.USD","BK4599","LXRX","NVOH","PPH","LU1093756168.USD","THNR","NVO","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661279033","title":"Lexicon earns third $10M milestone payment from Novo Nordisk for LX9851","url":"https://stock-news.laohu8.com/highlight/detail?id=2661279033","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661279033?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:45","pubTimestamp":1787575521,"startTime":"0","endTime":"0","summary":"Lexicon (LXRX) announced that it has earned a third $10M milestone payment in 2026 from Novo Nordisk (NVO) following the achievement of a patient d...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexicon-earns-third-10m-milestone-payment-from-novo-nordisk-for-lx9851-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexicon-earns-third-10m-milestone-payment-from-novo-nordisk-for-lx9851-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVOX","BK4588","IE00BKVL7J92.USD","OZEM","NVOH","BK4599","PPH","BK4585","BK4532","IE00BZ1G4Q59.USD","NVOC","LU0154236417.USD","LU1093756325.SGD","THNR","LXRX","NVO","BK4007","BK4139","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194806564","title":"Hong Kong Memory Chip Stocks Plunge as Samsung Drops Nearly 8%, Leveraged Product Sinks 16%","url":"https://stock-news.laohu8.com/highlight/detail?id=1194806564","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194806564?lang=en_us&edition=fundamental","pubTime":"2026-08-24 11:00","pubTimestamp":1787540434,"startTime":"0","endTime":"0","summary":"On August 24, memory chip stocks listed in Hong Kong experienced a broad decline, with the Southern Double Leveraged Samsung Electronics product plummeting 16%. Meanwhile, GigaDevice and VIA...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPYQ","BK4585","SMAX","NVOX","MUYY","SDS","MUZ","MUU","VOO","SPXU","DMAX","RGTU","NVTX","DRMP","BK4007","VXUS","EMXC","LITG","RGTC","RGTX","RGYY","IVV","SAA","07347","DRAL","NBIG","DRAM","SPYM","COZX","NBIC","MULL","VRTL","RAMZ","SSO","VRC","XW","LITC","LITU","BK4588","NVTC","09747","LABX","MVV","SSNLF","NEBX","BK4170","07747","NVOH","UPRO","MUD","ONTX","SPYH","NBIL","DISK","MMAX","MUG","BK4543","SPY","SPDN","SPXL","HIBL","RAM","LITZ","TEUP","YSPY","KCAI","RGTZ","SPUU","SPXS","HBMX","MIC","SPYU","LITX","NVOC","NBIZ","ETNG","OSSL","SIMX","FTXL","SH","ALA","DRMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188493561","title":"South Korea Sees Surge in Seized Illegal Weight-Loss Drugs, Tripling Last Year's Total in Just Six Months","url":"https://stock-news.laohu8.com/highlight/detail?id=1188493561","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188493561?lang=en_us&edition=fundamental","pubTime":"2026-08-24 10:04","pubTimestamp":1787537081,"startTime":"0","endTime":"0","summary":"Customs data released on Monday reveals that seizures of illegally imported weight-loss medications such as Wegovy and Mounjaro during the first half of this year have already surpassed the total for...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OZEM","NVOC","NVOX","NVOH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661729161","title":"Novo Nordisk A/S Series B Stock Rises Friday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2661729161","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661729161?lang=en_us&edition=fundamental","pubTime":"2026-08-22 00:02","pubTimestamp":1787328120,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novo Nordisk A/S Series B advanced 1.6% to DKK300.85 Friday on what proved to be an overall favorable trading session for the stock market, with the OMX Nordic 40 Index rising 1.1% to 2,717.75.The company closed DKK109.10 below its 52-week high of DKK409.95, which the company reached on January 23, 2026.Trading volume was 3,754,463, compared to the 50-day average trading volume of 4,322,923.Data source: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE00BKVL7J92.USD","BK5011","PPH","NVOC","THNR","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4599","NVOX","BK4585","LU1093756325.SGD","NVOH","BK4532","BK4588","NVO","OZEM","LU0154236417.USD","0QIU.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660286459","title":"Novonesis Expects Results from Weight-Loss Drug Supplement Study in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2660286459","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660286459?lang=en_us&edition=fundamental","pubTime":"2026-08-20 19:08","pubTimestamp":1787224108,"startTime":"0","endTime":"0","summary":"Novonesis expects results from weight-loss drug supplement study in 2027Aug 20 (Reuters)-Danish biosolutions maker NovonesisNSISb.COexpects results in the second half of 2027 from research with Novo N","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nL8N44H0HA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","LU0154236417.USD","BK4532","LU1093756168.USD","THNR","BK4588","BK4109","IE00BZ1G4Q59.USD","NVZMY","LU1093756325.SGD","OZEM","BK4585","NVOH","IE00BKVL7J92.USD","PPH","NVO","NVOX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660333420","title":"Moderately bullish activity in Novo Nordisk with shares up 1.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660333420","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660333420?lang=en_us&edition=fundamental","pubTime":"2026-08-20 02:05","pubTimestamp":1787162721,"startTime":"0","endTime":"0","summary":"Moderately bullish activity in Novo Nordisk (NVO), with shares up 60c, or 1.32%, near $46.31. Options volume running well above average with 83k co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moderately-bullish-activity-in-novo-nordisk-with-shares-up-1-32-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moderately-bullish-activity-in-novo-nordisk-with-shares-up-1-32-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4599","NVOH","BK4588","NVO","OZEM","IE00BZ1G4Q59.USD","LU1093756168.USD","THNR","IE00BKVL7J92.USD","PPH","NVOX","BK4007","LU0154236417.USD","LU1093756325.SGD","BK4585","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660226594","title":"Novo Nordisk Adds a New Early-Stage Obesity Drug to Its Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2660226594","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660226594?lang=en_us&edition=fundamental","pubTime":"2026-08-20 00:31","pubTimestamp":1787157069,"startTime":"0","endTime":"0","summary":"Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk A/S (NVO) is running a Phase 1 study called “An NNC6022-0004 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-adds-a-new-early-stage-obesity-drug-to-its-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-adds-a-new-early-stage-obesity-drug-to-its-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4599","LU0154236417.USD","BK4532","LU1093756168.USD","THNR","BK4588","IE00BZ1G4Q59.USD","LU1093756325.SGD","OZEM","BK4585","NVOH","IE00BKVL7J92.USD","PPH","NVO","NVOX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660842442","title":"Novo Nordisk A/S Series B Stock Rises Wednesday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2660842442","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660842442?lang=en_us&edition=fundamental","pubTime":"2026-08-20 00:02","pubTimestamp":1787155320,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novo Nordisk A/S Series B advanced 1.0% to DKK299.45 Wednesday on what proved to be an overall positive trading session for the stock market, with the OMX Nordic 40 Index rising 0.1% to 2,687.50.This was the stock's second consecutive day of gains.The company closed DKK110.50 below its 52-week high of DKK409.95, which the company reached on January 23, 2026.Trading volume was 4,427,716, compared to the 50-day average trading volume of 4,379,076.Data source: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","OZEM","BK4599","LU1093756325.SGD","BK4585","BK4532","IE00BZ1G4Q59.USD","THNR","NVOH","LU0154236417.USD","NVOX","LU1093756168.USD","BK4007","IE00BKVL7J92.USD","PPH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660284553","title":"These ‘Innovative’ ETFs Have Been Disastrous for Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2660284553","media":"Morning Star","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660284553?lang=en_us&edition=fundamental","pubTime":"2026-08-20 00:00","pubTimestamp":1787155200,"startTime":"0","endTime":"0","summary":"Morningstar Direct. Data as of Aug. 14, 2026. The ETF Spaghetti CannonSingle-stock ETF issuers are happy to launch dozens of ETFs tracking a variety of stocks because of the potentially huge asset growth an ETF can experience when a stock takes off—hence the proverbial spaghetti cannon, firing wildly at the wall to see what sticks.The spaghetti cannon approach works much better for ETF issuers than investors. Issuers seek out the most volatile stocks—like red-hot companies tied to artificia","market":"nz","thumbnail":"https://media.morningstar.com/resizer/v2/MMLNPYXF6BEHTGA7ROLQJUHSMM.png?auth=8686226ce05d329b36f41778f7b429b2f5464b2d3d9303f2cb1e48f44bc20cae&quality=80&height=1350&width=2400&crop=0,0:2400,1350","type":0,"news_type":0,"thumbnails":["https://media.morningstar.com/resizer/v2/MMLNPYXF6BEHTGA7ROLQJUHSMM.png?auth=8686226ce05d329b36f41778f7b429b2f5464b2d3d9303f2cb1e48f44bc20cae&quality=80&height=1350&width=2400&crop=0,0:2400,1350"],"rights":{"source":"morningstar_fund_highlight","url":"https://www.morningstar.com/funds/these-innovative-etfs-have-been-disastrous-investors","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.morningstar.com/funds/these-innovative-etfs-have-been-disastrous-investors","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"morningstar_fund_highlight","symbols":["TSLQ","AAPB","TSLY","MSFO","XNDX","TESL","MSFW","AAPD","APLY","AAPU","FDN","TSLG","AAPX","AAPY","ISBC","CRSH","TSDD","TSLI","NVOX","TSLO","TSLP","ELOL","TEST","TSLS","EO","MSFY","TLA","09366","TSLL","NVOH","TSII","AAPE","QNTU","09766","SMRX","AAPW","TSYY","07766","WX","TSL","TSLT","LITU","MSFU","MSFX","MSFL","TSLW","07366","TSLR","MSFD","TSLZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660421798","title":"Why 2026 is Biotech's Comeback Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2660421798","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660421798?lang=en_us&edition=fundamental","pubTime":"2026-08-19 23:16","pubTimestamp":1787152560,"startTime":"0","endTime":"0","summary":"This article was originally published on April 1, 2026. It has been updated to reflect recent developments.After a rough past few years, the biotech sector looks to be turning a corner. Major pharmace","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1267930730.SGD","LU1868836757.USD","FTXH","AGNG","LU0154236417.USD","LU2471134952.CNY","LU2491049909.HKD","LU2491050154.USD","IBB","LU0345770308.USD","LU2361045086.USD","LU2552382215.SGD","LU2108987350.USD","IE00B7KXQ091.USD","BK4139","IE00B1BXHZ80.USD","LU0158827781.USD","LU0234572021.USD","LU2023251221.USD","LU2746668461.USD","LU1868837136.USD","LU2552382058.USD","FHLC","THNR","BK4581","MRNX","SGXZ81514606.USD","LU1691799644.USD","LU2237443622.USD","LU0109391861.USD","IBBQ","LU0354030511.USD","LU0943347566.SGD","BK4585","LU0079474960.USD","BK4588","LU2089283258.USD","LU2168564065.EUR","PPH","SG9999001176.SGD","LU0289739699.SGD","LU0354030438.USD","LU1093756168.USD","LU0672654240.SGD","IE00BK4W5L77.USD","LU0094547139.USD","LU0203201768.USD","LU0353189680.USD","BK4568","LU1069344957.HKD","LU0964807845.USD","LU0466842654.USD","LU1548497426.USD","LU2237443895.HKD","SG9999015945.SGD","LU1057294990.SGD","BK4551","LU0158827948.USD","LU0683600562.USD","LU2756315318.SGD","LU0058720904.USD","BBH","IE0004445239.USD","MRNA","LU1720051017.SGD","LU2112291526.USD","LU2746668974.SGD","SGXZ99366536.SGD","IE00B4JS1V06.HKD","LU2089984988.USD","LU2242652126.USD","LU2361044865.SGD","SGXZ51526630.SGD","IE00BKPKM429.USD","LU0823434740.USD","LU2111349929.HKD","LU1280957306.USD","LU2211815571.USD","LU0133085943.USD","AMGN","BK4599","LU2552382132.HKD","LU2750360997.AUD","LU2417539215.USD","LU1551013425.SGD","GDOC","LU0786609619.USD","TMED","IE0004445015.USD","TRUH","IE00BJJMRY28.SGD","SG9999018857.SGD","CURE","SG9999014914.USD","LU2087625088.SGD","LU2237443465.HKD","LU1061106388.HKD","BK4566","IXJ","LU0417517546.SGD","SG9999015986.USD","LU1917777945.USD","LU2213496289.HKD","IE0001KFT4U8.USD","04332","IE00B2B36J28.USD","LU0320765992.SGD","LU1127390331.HKD","LU2168563687.JPY","OZEM","MHIP","WDNA","LU2461242641.AUD","LU0320765059.SGD","LU0820562030.AUD","IE00B1XK9C88.USD","LLY","BK4534","LU0114720955.EUR","LU0868494617.USD","LU2756315664.SGD","SGXZ57979304.SGD","LU2237443549.SGD","SG9999018865.SGD","LU2360106947.USD","SG9999014880.SGD","LU0456855351.SGD","LU0316494557.USD","LU2471134523.USD","LU0708995401.HKD","LU1232071149.USD","SG9999001176.USD","LU0882574139.USD","MEDI","LU0385154629.USD","LU1623119135.USD","SG9999014906.USD","LU2106854487.HKD","SGXZ31699556.SGD","BK4548","LU0889565916.HKD","LU0820561909.HKD","LU0256863902.USD","IE00BKVL7J92.USD","LU1814569148.SGD","IE00BFSS7M15.SGD","LU0225283273.USD","LU2168564495.EUR","LU2750360641.GBP","LU0174119429.USD","LU0109394709.USD","BIB","LU1064131342.USD","LU1551013342.USD","LU2456880835.USD","LU1804176565.USD","LU1983299246.USD","LU0882574055.USD","LU2265009873.SGD","SG9999013999.USD","LU1023059063.AUD","LU1712237335.SGD","LU1323610961.USD","IE00B4R5TH58.HKD","LU0096364046.USD","LU0823416689.USD","NVO","ELIS","LU2236285917.USD","BK4533","LU2324357040.USD","LU2168564149.EUR","LU1145028129.USD","LU1366192091.USD","LU0323591593.USD","MEDX","SG9999017495.SGD","CANC","IHE","GNOM","IE00BJJMRX11.SGD","IE00BWXC8680.SGD","LU1629891620.HKD","LU1979441026.SGD","IE0002141913.USD","LU1974910355.USD","LU0061475181.USD","RXL","LU2237443978.SGD","LU2237443382.USD","LU1291159041.SGD","IDNA","IE00BKDWB100.SGD","LU0640476718.USD","LU0122379950.USD","PBE","LU1868836914.USD","LU0256863811.USD","LU1571399168.USD","LU0238689110.USD","LGHT","LU2023250330.USD","LLYX","LU0432979614.USD","HRTS","LU0787776722.HKD","LU1868837300.USD","LU2361044949.HKD","IE00B775H168.HKD","LU2028103732.USD","IE00BZ1G4Q59.USD","TBXU","IE00BN29S564.USD","LU2023250504.SGD","LU0006306889.USD","BK4007","BK4532","GB00BDT5M118.USD","LU0097036916.USD","LU0689472784.USD","LU1989771016.USD","LU2089284900.SGD","LU2471134879.HKD","LU0823434583.USD","LU1720051108.HKD","IE0009355771.USD","LU2264538146.SGD","LU2357305700.SGD","LU2242646821.SGD","LU0266013472.USD","LU0820561818.USD","LU0198837287.USD","NVOH","VHT","SG9999001440.SGD","LU0203202063.USD","LU2462157665.USD","ILDR","LU2063271972.USD","IE00BK4W5M84.HKD","LU2491050071.SGD","LU1093756325.SGD","LU0106261372.USD","MRNY","SG9999015952.SGD","LU2896262040.SGD","IYH","SG9999014898.SGD","LU2168564222.USD","LU2602419157.SGD","LLII","LU2468319806.SGD","LU1868836591.USD","BK4501","LU0353189763.USD","LU2471134796.USD","NVOX","LU0210536198.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU0471298777.SGD","LU2271345857.HKD","IE0005OL40V9.USD","XLV","LU0471298694.HKD","SG9999015978.USD","LU2237438978.USD","ELIL","LU0345770993.USD","LU1988902786.USD","PJP","IE00BFSS8Q28.SGD","LU2462591350.SGD","LLYZ","LU1035775433.USD","IE00BJT1NW94.SGD","IE00BJLML261.HKD","JDOC","BK4516"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660842655","title":"Novo Nordisk testing lower doses of oral Wegovy, Reuters reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2660842655","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660842655?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:41","pubTimestamp":1787146871,"startTime":"0","endTime":"0","summary":"Novo Nordisk (NVO) is testing lower doses of oral Wegovy to identify the minimum effective dose, a move that could improve tolerability, accessibil...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novo-nordisk-testing-lower-doses-of-oral-wegovy-reuters-reports-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novo-nordisk-testing-lower-doses-of-oral-wegovy-reuters-reports-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4599","LU0154236417.USD","NVOH","BK4532","OZEM","LU1093756168.USD","BK4585","NVOX","PPH","BK4588","IE00BKVL7J92.USD","BK4007","NVO","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660428261","title":"Novo Nordisk Starts Testing Lower-Doses of Its Wegovy Weight-Loss Pills","url":"https://stock-news.laohu8.com/highlight/detail?id=2660428261","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660428261?lang=en_us&edition=fundamental","pubTime":"2026-08-19 20:17","pubTimestamp":1787141820,"startTime":"0","endTime":"0","summary":"Novo Nordisk is studying smaller doses of its Wegovy weight-loss pill to find the lowest dose that patients can take and still lose weight, according to a U.S. clinical trials database.The study, which began last week and will run into 2028, has enrolled 450 overweight people and will test two low doses of the pill compared to a placebo. The actual doses being used in the trial weren't disclosed.Novo Nordisk didn't immediately reply to a request for comment.Currently the lowest dose Wegovy pill available is 1.5 milligrams for the starter dose, with patients able to work their way up to the highest 25-milligram dose over time.Novo Nordisk recently disclosed that uptake of the pill has been particularly strong for its lowest doses across self-paying patients, which are also around half the price of the higher doses in the U.S.The Wegovy pill, which launched earlier this year in the U.S., logged sales of around $500 million in the second quarter, up from around $350 million in the first q","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","BK4585","LU0154236417.USD","NVOX","OZEM","PPH","BK4532","IE00BZ1G4Q59.USD","BK4007","BK4588","THNR","LU1093756325.SGD","BK4599","NVO","NVOH","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660449205","title":"Novo Nordisk Launches Dosage Study for Oral Semaglutide","url":"https://stock-news.laohu8.com/highlight/detail?id=2660449205","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660449205?lang=en_us&edition=fundamental","pubTime":"2026-08-19 17:35","pubTimestamp":1787132128,"startTime":"0","endTime":"0","summary":"Novo Nordisk  has initiated a study to see how oral semaglutide, when taken in lower doses, impacts body weight in participants with excess body weight when compared to a placebo, a regulatory filing said Tuesday.The primary endpoint aims to discern the optimal lower dose of oral semaglutide to treat overweight or obese patients, the filing said.The filing said the OASIS 5 study began Aug. 12 and is recruiting an estimated 450 participants.The study is estimated to be completed in April 2028.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4532","LU0154236417.USD","NVOH","THNR","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","NVOX","LU1093756168.USD","BK4585","BK4007","BK4599","NVO","OZEM","LU1093756325.SGD","PPH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107596134","title":"Pharmaceutical Giants Race to Develop Obesity Drugs Without Severe Side Effects","url":"https://stock-news.laohu8.com/highlight/detail?id=1107596134","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107596134?lang=en_us&edition=fundamental","pubTime":"2026-08-19 15:27","pubTimestamp":1787124455,"startTime":"0","endTime":"0","summary":"Blockbuster weight-loss medications such as Mounjaro and Wegovy have delivered massive sales figures for the major pharmaceutical companies that developed them.While these therapies have been widely...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOX","OZEM","NVOH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660496782","title":"Novo Nordisk Tests Semaglutide’s Alzheimer’s Potential: What Investors Should Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2660496782","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660496782?lang=en_us&edition=fundamental","pubTime":"2026-08-19 00:30","pubTimestamp":1787070635,"startTime":"0","endTime":"0","summary":"Novo Nordisk ($NVO) announced an update on their ongoing clinical study. The study, officially titled “A Randomised Double-blind Placebo-controlled...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-tests-semaglutides-alzheimers-potential-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-tests-semaglutides-alzheimers-potential-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4599","NVO","NVOH","OZEM","LU1093756325.SGD","BK4532","THNR","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4007","PPH","BK4588","LU0154236417.USD","LU1093756168.USD","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660464185","title":"BMO Capital Remains a Hold on Novo Nordisk (NVO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660464185","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660464185?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:37","pubTimestamp":1787053020,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Evan Seigerman from BMO Capital maintained a Hold rating on Novo Nordisk, with a price target of $47.00. The compan...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bmo-capital-remains-a-hold-on-novo-nordisk-nvo-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bmo-capital-remains-a-hold-on-novo-nordisk-nvo-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OZEM","BK4007","LU1093756325.SGD","IE00BZ1G4Q59.USD","BK4599","BMO","NVOH","BK4585","BK4588","BK4207","BK4532","LU0154236417.USD","LU1093756168.USD","NVO","IE00BKVL7J92.USD","NVOX","PPH","THNR"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}